Accepted for Publication: May 23, 2020.
Corresponding Authors: Vivian E. Strong, MD, Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065 (strongv@mskcc.org); Zsofia K. Stadler, MD, Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 122 E 70th St, New York, NY 10065 (stadlerz@mskcc.org).
Published Online: September 30, 2020. doi:10.1001/jamasurg.2020.3356
Author Contributions: Drs Stadler and Strong contributed equally to this work. Dr Strong had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Vos, Salo-Mullen, Tang, Janjigian, Stadler, Strong.
Acquisition, analysis, or interpretation of data: Vos, Salo-Mullen, Tang, Schattner, Yoon, Gerdes, Markowitz, Mandelker, Offitt, Coit, Stadler, Strong.
Drafting of the manuscript: Vos, Salo-Mullen, Offitt, Stadler.
Critical revision of the manuscript for important intellectual content: Salo-Mullen, Tang, Schattner, Yoon, Gerdes, Markowitz, Mandelker, Janjigian, Coit, Stadler, Strong.
Statistical analysis: Vos.
Administrative, technical, or material support: Salo-Mullen, Gerdes, Mandelker, Janjigian, Offitt, Coit, Strong.
Supervision: Tang, Schattner, Yoon, Offitt, Coit, Stadler, Strong.
Conflict of Interest Disclosures: Dr Yoon reported partial ownership of Attis Lab outside the submitted work. Dr Janjigian reported receiving personal fees from Eli Lilly, Michael J. Hennessy Associates, Zymeworks Inc, Jounce Therapeutics, Seattle Genetics, Rgenix, AstraZeneca, Daiichi Sankyo, ONO Pharma, Merck & Co Inc, Bristol Myers Squibb, Pfizer, Bayer, and Imugene and receiving research funding from Boehringer Ingelheim, Eli Lilly, Merck & Co Inc, Bristol Myers Squibb, Bayer, and Genentech/Roche outside the submitted work. Dr Stadler reported spouse’s consulting for Genentech/Roche, RegenexBio, Optos, Adverum, Allergan, Regeneron, BioMarin, and Spark Therapeutics outside the submitted work. No other disclosures were reported.
Funding/Support: This study was supported in part by Cancer Center Support Grant P30 CA008748 from the National Institutes of Health/National Cancer Institute.
Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Jessica Moore, MS, Memorial Sloan Kettering Cancer Center, edited the manuscript. She was compensated through her regular salary. Murray F. Brennan, MD, provided critical review to the manuscript. He was not compensated for his work.
5.Hebbard
PC , Macmillan
A , Huntsman
D ,
et al. Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients.
Ann Surg Oncol. 2009;16(7):1890-1895. doi:
10.1245/s10434-009-0471-z
PubMedGoogle ScholarCrossref 10.Barber
ME , Save
V , Carneiro
F ,
et al. Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk.
J Pathol. 2008;216(3):286-294. doi:
10.1002/path.2415
PubMedGoogle ScholarCrossref 11.Hüneburg
R , Marwitz
T , van Heteren
P ,
et al. Chromoendoscopy in combination with random biopsies does not improve detection of gastric cancer foci in CDH1 mutation positive patients.
Endosc Int Open. 2016;4(12):E1305-E1310. doi:
10.1055/s-0042-112582
PubMedGoogle ScholarCrossref 13.Carneiro
F , Huntsman
DG , Smyrk
TC ,
et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening.
J Pathol. 2004;203(2):681-687. doi:
10.1002/path.1564
PubMedGoogle ScholarCrossref 14.Charlton
A , Blair
V , Shaw
D , Parry
S , Guilford
P , Martin
IG . Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone.
Gut. 2004;53(6):814-820. doi:
10.1136/gut.2002.010447
PubMedGoogle ScholarCrossref 18.Lee
K , Krempely
K , Roberts
ME ,
et al. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline
CDH1 sequence variants.
Hum Mutat. 2018;39(11):1553-1568. doi:
10.1002/humu.23650
PubMedGoogle ScholarCrossref